A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
- Published In:
- European journal of clinical pharmacology, 80(5), 669-676 (2024)
- Authors:
- Kaur, Manmeet, Misra, Saurav
- Database ID:
- RPEP-08529
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08529APA
Kaur, Manmeet; Misra, Saurav. (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.. European journal of clinical pharmacology, 80(5), 669-676. https://doi.org/10.1007/s00228-024-03646-0
MLA
Kaur, Manmeet, et al. "A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.." European journal of clinical pharmacology, 2024. https://doi.org/10.1007/s00228-024-03646-0
RethinkPeptides
RethinkPeptides Research Database. "A review of an investigational drug retatrutide, a novel tri..." RPEP-08529. Retrieved from https://rethinkpeptides.com/research/kaur-2024-a-review-of-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.